Looking after the overlooked

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV, oncology and hepatology.

Most recent

January 20, 2021

B. Riley Securities Virtual Oncology Investor Conference

January 19, 2021

Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

January 15, 2021

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)

Making a difference

Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing niche therapeutic needs.

Our values

Agility

The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.

Tenacity

There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.

Commitment

We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our commercialized products

Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is only approved in the United States. EGRIFTA® is approved in the United States, Canada and Mexico but is no longer available in the United States.